Estonya - Estonca - Ravimiamet

norbrook laboratories limited - imidaklopriid - täpilahus - 250mg 2.5ml 6tk; 250mg 2.5ml 3tk; 250mg 2.5ml 24tk

Estonya - Estonca - Ravimiamet

elanco animal health gmbh - imidaklopriid - täpilahus - 40mg 0.4ml 0.4ml 4tk; 100mg 1ml 2.5ml 4tk; 100mg 1ml 4ml 4tk; 100mg 1ml 0.4ml 4tk

Estonya - Estonca - Ravimiamet

elanco animal health gmbh - imidaklopriid - täpilahus - 80mg 0.8ml 0.8ml 4tk

Estonya - Estonca - Ravimiamet

gedeon richter plc. - levonorgestreel - intrauteriinne ravivahend - 52mg 1tk

Estonya - Estonca - Ravimiamet

gedeon richter plc. - levonorgestreel - intrauteriinne ravivahend - 52mg 5tk; 52mg 1tk

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

biopartners gmbh - recombinant human interferon alfa-2a - c-hepatiit, krooniline - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

elanco gmbh - lotilaner, milbemycin oxime - endektokoidid - koerad - for use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimulants, - neutropeenia ja febriilse neutropeenia esinemissageduse vähendamine ravitud tsütotoksilise kemoteraapia pahaloomulise kasvaja (välja arvatud krooniline müeloidne leukeemia ja müelodüsplastilised sündroomid).

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

pharmaand gmbh - peginterferoon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 ja 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. seoses algatamise otsuse ravi lastel patsientidel, vt lõigud 4. 2, 4. 4 ja 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 ja 5. c-hepatiidi viiruse (hcv) genotüüp konkreetne tegevus, vt punktid 4. 2 ja 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. kui otsustatakse alustada ravi lapseeas, see on oluline kaaluda kasvu pidurdumine on põhjustatud kombineeritud ravi. pöörduvust, on majanduskasvu pidurdumine ei ole kindel. otsus ravida, tuleb teha iga juhtumi puhul eraldi (vt lõik 4.

Avrupa Birliği - Estonca - EMA (European Medicines Agency)

astrazeneca ab - eksenatiid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - byetta on näidustatud tüüp-2 diabeet koos:metformiin;sulphonylureas;thiazolidinediones;metformiin ja sulphonylurea;metformiin ja thiazolidinedione;täiskasvanutel, kes ei ole saavutanud piisavat glycaemic kontrolli kohta, maksimaalselt talutava annuse need suukaudne ravi. byetta on ka märgitud, et adjunctive ravi, et basaal insuliini või ilma metformiin ja / või pioglitazone täiskasvanutel, kes ei ole saavutanud piisavat glycaemic kontrolli need ained.